Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
